Navidea Biopharmaceuticals, Inc. has filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The company aims to conduct an orderly restructuring of its financial obligations while maintaining limited operations to preserve value for creditors and stakeholders. Epiq Corporate Restructuring, LLC has been appointed as the claims and noticing agent for the case, and interested parties can access court filings and case information via the Epiq website at https://dm.epiq11.com/Navidea.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Navidea Biopharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251008843839) on October 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.